Buruli Ulcer
11
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Telacebec (T) Treatment in Adults With Buruli Ulcer (BU).
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy
Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHO-recommended Wound Management in West Africa
Thermotherapy of Buruli Ulcer at Community Level in the Health District of Akonolinga
Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics
Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer
BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA